Tirzepatide
Also known as: Mounjaro, Zepbound, LY3298176, GIP/GLP-1 Dual Agonist
Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist that produces greater weight loss than semaglutide in head-to-head trials. SURMOUNT-1 trial showed average 21% body weight reduction at 72 weeks at the highest dose. Marketed as Mounjaro (diabetes) and Zepbound (obesity).
Half-Life
~5 days
Route
SubQ
Category
GLP-1 / Weight Loss Agonists
Studies
50 references
Key Benefits
- Average 21% body weight reduction at highest dose (SURMOUNT-1)
- Superior to semaglutide in head-to-head SURPASS trials
- Dual GIP/GLP-1 mechanism for enhanced metabolic control
- Significant reduction in HbA1c for type 2 diabetes
- Improved cardiovascular risk markers
- Reduces visceral fat preferentially
- FDA-approved for T2DM (Mounjaro) and obesity (Zepbound)
- Weekly dosing
Mechanism of Action
Tirzepatide is a synthetic 39-amino acid peptide that simultaneously activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors with balanced potency. GIP receptor activation enhances insulin secretion, promotes fat storage at physiological levels, but at pharmacological doses also promotes fat oxidation and reduces adipose inflammation. GLP-1 activation suppresses appetite and slows gastric emptying. The dual agonism produces additive metabolic benefits exceeding GLP-1 monotherapy.
Dosing Protocols
Weight Management Titration (Zepbound)
- Dose
- 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg
- Frequency
- Once weekly, subcutaneous
- Timing
- Same day each week; any time of day
- Cycle
- Titration over 20+ weeks; ongoing maintenance at highest tolerated dose
Start at 2.5 mg/week for 4 weeks. Increase by 2.5 mg every 4 weeks as tolerated. Maximum FDA-approved dose 15 mg/week. Slower titration reduces GI side effects significantly.
Type 2 Diabetes (Mounjaro)
- Dose
- 2.5 mg → 5 mg → 10 mg → 15 mg
- Frequency
- Once weekly, subcutaneous
- Timing
- Same day each week
- Cycle
- Ongoing per physician
FDA-approved for T2DM management. Starting dose 2.5 mg, titrated up based on glucose response and tolerability.
Calculate your draw volume
Enter your vial size and BAC water to get exact injection volumes
Side Effects
- Nausea (most common during titration)
- Vomiting
- Diarrhea or constipation
- Abdominal pain
- Fatigue
- Injection site reactions
- Rare: pancreatitis, gallbladder disease
Contraindications
Personal or family history of medullary thyroid cancer or MEN2 syndrome (black box warning). Pregnancy or breastfeeding. Severe GI disease. History of pancreatitis.
Storage
Store pre-filled pens in refrigerator (2–8°C). Can store at room temperature (up to 30°C) for up to 21 days after first use. Do not freeze.
Featured In Stacks
GLP-1 Comprehensive Obesity & Metabolic Reset
Structured GLP-1 agonist protocol for significant weight loss using dose escalation from Semaglutide to Tirzepatide or Retatrutide. Combines gut hormone axis modulation with metabolic enhancers.
Medically Supervised Extreme Weight Loss Protocol
Maximum-intensity peptide protocol for significant obesity (BMI 35+) combining multiple lipolytic, appetite-suppressing, and metabolic-restoring mechanisms under medical supervision.
NAFLD & Metabolic Liver Disease Protocol
A comprehensive protocol targeting non-alcoholic fatty liver disease and metabolic-associated steatohepatitis (MASH) through GLP-1 receptor agonism, AMPK activation, and mitochondrial support to reduce hepatic fat and inflammation.
Clinical Research
- 1.Tirzepatide Combined With Continuous Positive Airway Pressure Treatment in Obstructive Sleep Apnoea Syndrome With Comorbid Obesity: Effects on Weight, Daytime Sleepiness, and Cognitive Performance
Fernandes M, Antonucci M, Testone G, Bergamo G, Liguori C · Diabetes, obesity & metabolism · 2026PubMed Verified
- 2.Dose-Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting
Nauck MA, Punov V, Kang YM, Lim S · Diabetes, obesity & metabolism · 2026PubMed Verified
- 3.Probable Tirzepatide-Induced Rhabdomyolysis in an HIV-Positive Patient
Wells DA, Duncan K, Sakaan S · Hospital pharmacy · 2026Case ReportPubMed Verified
- 4.Tirzepatide ameliorates type 2 diabetes-associated male reproductive dysfunction via modulation of the Nrf2/Keap1 pathway
Albokhadaim I · Toxicology research · 2026PubMed Verified
- 5.A Narrative Review on GLP-1 Receptor Agonists for Obesity in Older Women: Maximizing Weight Loss While Preserving Lean Mass
Moscucci F, Baratta F, Pastori D, Menichelli D, Mattioli AV, Gallina S et al. · Nutrients · 2026ReviewPubMed Verified
- 6.Comment on 'Semaglutide and Tirzepatide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World (STEER)'
Wang CY · Diabetes, obesity & metabolism · 2026PubMed Verified
- 7.Musculoskeletal adverse events with incretin-based diabetes drugs: a FAERS pharmacovigilance study
Guo M, Chen S, Dong H, Cai M, Guo M, Cheng H · Naunyn-Schmiedeberg's archives of pharmacology · 2026PubMed Verified
- 8.Tirzepatide-Associated Euglycemic Diabetic Ketoacidosis in the Absence of Sodium-Glucose Cotransporter-2 Inhibitor Use: A Case Report
Campana C, Heaney A, Ceraolo N, Srinivas S, Simon EL · The Journal of emergency medicine · 2026PubMed Verified
- 9.Effect of GLP-1 Receptor Agonists in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis
Behers BJ, Sanchez C, Hozayen O, Hozayen Y, Kammer R, Corrigan WT et al. · Journal of cardiovascular development and disease · 2026ReviewPubMed Verified
- 10.Overview of Diabetes Medications: Traditional and New-Generation Agents and Their Off-Label Use for Weight Loss
Castellana E, Budau PM, Chiappetta MR · The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2026ReviewPubMed Verified
- 11.Adverse events associated with tirzepatide: a focus on subgroup-specific differences
Yu Z, Qi Y, Gan Q, Wu G, Zhang X, Jiang C et al. · BMC pharmacology & toxicology · 2026PubMed Verified
- 12.Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs in the FDA Adverse Event Reporting System
Seijas-Amigo J, Salgado-Barreira Á, Rodriguez-Penas D, Cardeso-Paredes B, Ribeiro-Ferreiro M, Rodriguez-Mañero M et al. · International journal of clinical pharmacy · 2026PubMed Verified
- 13.Obesity medications and precision nutrition: synergistic interventions and integrated approach in obesity management
Feraco A, Camajani E, Muscogiuri G, Barrea L, Colao A, Caprio M · Current obesity reports · 2026ReviewPubMed Verified
- 14.Weight regain after bariatric surgery: A framework for management
Niedbala CG · JAAPA : official journal of the American Academy of Physician Assistants · 2026ReviewPubMed Verified
- 15.Pre-Treatment Concerns and Their Association With Functioning and Well-Being During Incretin-Based Therapy: A Cross-Sectional Study
Kapan A, Brandl T, Waldhör T, Moser O, Felsinger R · Diabetes, obesity & metabolism · 2026PubMed Verified
- 16.Reduced-Frequency GLP1 Therapy Maintains Weight, Body Composition, and Metabolic Syndrome Improvements: A Case Series
Wong M, Wu A, Garhe PK, Biermann M · Obesity (Silver Spring, Md.) · 2026PubMed Verified
- 17.Treatment preferences for comorbid obesity and obstructive sleep apnea (PRO-CON OSA) survey: Patient and provider preferences for CPAP and/or tirzepatide
Schmickl CN, Tripipitsiriwat A, Mokhlesi B, Mallampalli M, Nokes B, Kundel V et al. · Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2026PubMed Verified
- 18.Cardiovascular benefits of obesity therapies: an overview of obesity medicines and metabolic bariatric surgery
Villelabeitia IK, Cohen R, le Roux CW · Heart (British Cardiac Society) · 2026ReviewPubMed Verified
- 19.Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Therapy for Hidradenitis Suppurativa in Patients With Overweight/Obesity: A Narrative Review of Efficacy, Safety, and Quality-of-Life Outcomes
Almukhadeb E, Nagshabandi KN, Alshehri N, Alosaimi K, Almusa HA, Almudimeegh A · International journal of dermatology · 2026ReviewPubMed Verified
- 20.Comparative effectiveness of continuous positive airway pressure and glucagon-like peptide-1 receptor agonists in obstructive sleep apnea: A network meta-analysis of randomised trials
Chiappa GR, Santos PCN, Cavalcante DVS, Sá Filho AS, Prado N, Lombardo KM et al. · Diabetes, obesity & metabolism · 2026ReviewPubMed Verified
- 21.Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison
Hitaka K, Sugawara T, Matsumoto M, Nio Y · International journal of obesity (2005) · 2026PubMed Verified
- 22.Head-to-head comparison of tirzepatide and semaglutide for weight loss: A systematic review and meta-analysis
Zufry H, Hariyanto TI · Obesity research & clinical practice · 2026PubMed Verified
- 23.Obesity in Type 1 Diabetes: Moving Beyond the "Lean" Disease Paradigm to Understand Risk, Complications, and Treatment
Tentolouris A, Koufakis T, Fousteris E · Current obesity reports · 2026ReviewPubMed Verified
- 24.The role of Race and Ethnicity in the response to MASLD treatment: A Review
Laurence A, Gandhi SM, Nylen ES, Sen S · Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2026ReviewPubMed Verified
- 25.The effect of combining surgical or endoscopic bariatric interventions with anti-obesity medication or probiotics on weight loss: a narrative review
de Waal JR, Nieuwdorp M, Gerdes VEA · Frontiers in endocrinology · 2026ReviewPubMed Verified
- 26.Beyond weight loss: Effect of GLP-1 receptor agonist therapy on the urological health
Tariq A, Garza Gangemi A, Herrera Caceres J · Urology case reports · 2026Case ReportPubMed Verified
- 27.Efficacy and safety of anti-prediabetic drugs in patients with prediabetes: a Bayesian network meta-analysis
Wu Y, Wang Z, Tuersun A, Yu Q, Zhong Y, Ali SSA et al. · BMC medicine · 2026PubMed Verified
- 28.Correction to "Efficacy and safety in tirzepatide-treated Korean adults with type 2 diabetes-A post hoc analysis of SURPASS-AP-combo and SURPASS-3"
Diabetes, obesity & metabolism · 2026PubMed Verified
- 29.Semaglutide vs tirzepatide in patients with obesity and HFpEF: a report from a global federated research network
Monzo L, Savarese G, Duarte K, Baudry G, Petrie MC, Girerd N · ESC heart failure · 2026PubMed Verified
- 30.Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis
Chan ZH, Omar AS, Gill K, Volucke G, Azhar MM, Haleem SM et al. · Cardiology in review · 2026PubMed Verified
- 31.Established and emerging pharmacologic options and unmet need in HFpEF and HFmrEF
Sauer AJ, Ter Maaten JM, Savarese G · ESC heart failure · 2026PubMed Verified
- 32.Revitalizing GIP: Therapeutic Potential in Metabolic and Neurodegenerative Disorders
Qiao Y, Zhou F, Mao T, Gao L · Diabetes, metabolic syndrome and obesity : targets and therapy · 2026ReviewPubMed Verified
- 33.A Clinical Comprehensive Evaluation of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes Management
Chen Q, Chen T, Lin W, Chen X · Diabetes, metabolic syndrome and obesity : targets and therapy · 2026PubMed Verified
- 34.Dual GIPR and GLP-1R Agonist Tirzepatide Is Associated With Fewer Asthma Exacerbations in Adults With Obesity
Mehta S, Gillani SF, Elkomi R, Michael M · Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026PubMed Verified
- 35.Use (and Potential for Abuse) of Glucagon-Like Peptide-1 Medications Among Individuals with Eating Disorders: Empirical Review and Clinical Guidance
Schaefer LM, Kerver GA, Allison KC, Kohoutek B, Steffen KJ · The Psychiatric clinics of North America · 2026ReviewPubMed Verified
- 36.Challenges in the management of obesity
Smith BL, May A, Lalani F, Hasham S, Presnell AA · Journal of clinical lipidology · 2026ReviewPubMed Verified
- 37.Risk of New-Onset Hair Loss with Semaglutide and Tirzepatide: A TriNetX Cohort Study
Herrera HO, Bordeaux JS · Journal of the American Academy of Dermatology · 2026PubMed Verified
- 38.Tirzepatide in solid organ transplant recipients: Early real-world signals of efficacy and safety-A narrative review
Corrêa LMA, Mazur GR, Santiago CBG, Dante LE, de Marco PS, Ferrés PBS · Transplantation reviews (Orlando, Fla.) · 2026ReviewPubMed Verified
- 39.Tirzepatide on physical function in adults with overweight or obesity: A systematic review and meta-analysis
Schmidt PHS, de Souza VSN, Machado LG, Rodrigues JVA, da Cruz JVR, de Souza LSN et al. · Diabetes, obesity & metabolism · 2026PubMed Verified
- 40.
- 41.Comparative efficacy of GLP-1 RA, tirzepatide and SGLT-2 inhibitors in metabolic liver disease: A network meta-analysis
Belančić A, Antza C, Poutachidis A, Palaska S, Gkrinia EMM, Faour AK et al. · British journal of clinical pharmacology · 2026PubMed Verified
- 42.GLP-1 and the cardiovascular system
Kahles F, Birkenfeld AL, Marx N · The Journal of clinical investigation · 2026ReviewPubMed Verified
- 43.Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov
Patil S, Jha N, Jha MK · Addictive behaviors reports · 2026PubMed Verified
- 44.Advances in the Pharmacological Treatment of Heart Failure With Preserved Ejection Fraction
Valente V, Beer BN, Savarese G · International journal of heart failure · 2026ReviewPubMed Verified
- 45.Ischemic Colitis Associated With Tirzepatide Therapy in a Young Female Patient: A Case Report
Sekhon S, Kahlon I, Latson W · Cureus · 2026Case ReportPubMed Verified
- 46.Tirzepatide
2006ReviewPubMed Verified
- 47.Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown
Belcourt J, Sapowadia A, White CM · The Annals of pharmacotherapy · 2026PubMed Verified
- 48.Prospective Comparative Analysis of Synchronous Abdominoplasty and Mastopexy in Bariatric and Nonbariatric Massive Weight Loss Patients: Highlighting the Rising Trend of GLP-1 Analog Use
Menkü Özdemir FD, Uzun H · Annals of plastic surgery · 2026PubMed Verified
- 49.Cardio-Obesity and Therapeutic Advances: Intersections Between Excess Adiposity, Cardiovascular Risk, and Pharmacologic Interventions
De Oliveira-Gomes D, de Majo AM, Ardila-Delgado A, Inglis SS, Mandras SA, Loro-Ferrer JF et al. · Current atherosclerosis reports · 2026ReviewPubMed Verified
- 50.Comparing Telepharmacy to Conventional Pharmacy Care: An Economic Evaluation
Tam S, Persaud V, Wertheimer A · Journal of pharmacy practice · 2026PubMed Verified
Medical disclaimer: This information is for educational purposes only and does not constitute medical advice. Many compounds listed are research chemicals not approved for human use. Always consult a qualified healthcare professional before starting any protocol.
Was this page helpful?
Launching soon
Build and track your protocol in Staqk
Log doses, track timing, monitor biomarkers, and manage every compound in your stack — all in one place.